Ru Tang1,2,3, Yujia Zhai3, Lili Dong3,4, Tejsu Malla3, Kai Hu1,5. 1. Department of Ophthalmology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, Jiangsu, China. 2. Department of Ophthalmology, The People's Hospital of Danyang, Zhenjiang, Jiangsu, China. 3. Department of Ophthalmology, Zhongda Hospital, Southeast University, Nanjing Jiangsu, China. 4. Department of Ophthalmology, Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu, China. 5. Nanjing Ning Yi Eye Center, Nanjing, Jiangsu, China.
Abstract
AIM: The aim of this study is to investigate the effects of constructed dendritic cell (DC)-based DNA vaccine (pRSC-NLDC145.gD-IL21) carried by chitosan nanoparticle in preventing primary or recurrent herpes simplex virus keratitis (HSK) in mice. METHODS: The expression of constructed plasmid 'pRSC-NLDC145.gD-IL21' was verified by western blot and immunofluorescence. Plasmids that were embedded in chitosan were inoculated to test its therapeutic effect against primary or recurrent HSK in mice. Humoral and cellular immune response, clinical scores of herpes keratitis and inflammatory infiltration were measured. RESULTS: The expressed glycoprotein D (gD) of pRSC-NLDC145.gD-IL21 DNA/chitosan nanoparticle vaccine could effectively target corneal DCs and significantly alleviate the symptoms of both primary and recurrent HSK mice via eliciting strong humoral and cellular immune response. CONCLUSION: Our data suggested that DC-based DNA vaccine could be a better choice for HSK treatment in the future.
AIM: The aim of this study is to investigate the effects of constructed dendritic cell (DC)-based DNA vaccine (pRSC-NLDC145.gD-IL21) carried by chitosan nanoparticle in preventing primary or recurrent herpes simplex virus keratitis (HSK) in mice. METHODS: The expression of constructed plasmid 'pRSC-NLDC145.gD-IL21' was verified by western blot and immunofluorescence. Plasmids that were embedded in chitosan were inoculated to test its therapeutic effect against primary or recurrent HSK in mice. Humoral and cellular immune response, clinical scores of herpes keratitis and inflammatory infiltration were measured. RESULTS: The expressed glycoprotein D (gD) of pRSC-NLDC145.gD-IL21 DNA/chitosan nanoparticle vaccine could effectively target corneal DCs and significantly alleviate the symptoms of both primary and recurrent HSK mice via eliciting strong humoral and cellular immune response. CONCLUSION: Our data suggested that DC-based DNA vaccine could be a better choice for HSK treatment in the future.